Magnesium sulfate tocolysis: Time to quit [4]

Obstetrics and Gynecology

Volumn 109, Issue 5, 2007, Pages 1204-1205

  Mittendorf, Robert ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; PLACEBO;

BRAIN INJURY; CEREBRAL PALSY; CLINICAL RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; LOW DRUG DOSE; NEUROPROTECTION; NEWBORN MORTALITY; PRIORITY JOURNAL; TOCOLYSIS; WHITE MATTER;

FEMALE; HUMANS; MAGNESIUM SULFATE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; TOCOLYSIS; TOCOLYTIC AGENTS;

EID: 34247584608     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000263775.75185.1e     Document Type: Letter

References (4)

1. 4) and neuroprotection in preterm infants: a randomised controlled trial. PAS 2005:57:1547.
2. Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;163: 767-72.
3. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669-76.
4. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.